Director Kenneth Harrison resigns from Edgewise board; company to cure Audit Committee vacancy under Nasdaq rules

Edgewise Therapeutics, Inc.

Kenneth Harrison, Ph.D. resigned from Board and all committees effective June 19, 2023; not due to disagreement.
Resignation leaves Audit Committee with fewer than three members, violating Nasdaq Listing Rule 5605(c)(2)(A).
Company notified Nasdaq on June 21, 2023 and will use cure period under Rule 5605(c)(4)(B) to regain compliance.
Edgewise is evaluating board and committee membership to fill vacancy and restore compliance.

item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kenneth Harrison

Director

EWTX · Edgewise Therapeutics, Inc.

Effective: 2023-06-19
Filed: June 22, 2023, 7:59 PM ET

On June 19, 2023, Kenneth Harrison, Ph.D. informed the Board that he was resigning from the Board and all of its committees, effective on such date

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kenneth Harrison resigned as Director at Edgewise Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On June 19, 2023, Kenneth Harrison, Ph.D. informed the Board that he was resigning from the Board and all of its committees, effective on such date

View on SEC.gov

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-073465

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.